UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040600
Receipt number R000046332
Scientific Title Safety of bronchoalveolar lavage for severe acute respiratory failure: systematic review and meta-analysis
Date of disclosure of the study information 2020/05/31
Last modified on 2021/10/13 11:50:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety of bronchoalveolar lavage for severe acute respiratory failure: systematic review and meta-analysis

Acronym

Safety of bronchoalveolar lavage for severe acute respiratory failure: systematic review and meta-analysis

Scientific Title

Safety of bronchoalveolar lavage for severe acute respiratory failure: systematic review and meta-analysis

Scientific Title:Acronym

Safety of bronchoalveolar lavage for severe acute respiratory failure: systematic review and meta-analysis

Region

Japan


Condition

Condition

Acute respiratory distress syndrome/acute lung injury, and severe respiratory failure

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verification of safety and adverse events of bronchoalveolar lavage in patients with ARDS/ALI and severe respiratory failure

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Death or serious disability

Key secondary outcomes

1) Life-threatening adverse events (e.g., exacerbation of respiratory status requiring new treatment, arrhythmias requiring intervention, reduction in blood pressure requiring intervention ,etc.)
2) Minor adverse events (e.g., temporary worsening of oxygenation)


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with severe respiratory failure such as acute respiratory distress syndrome and acute lung injury (also acceptable as defined by the authors) who were performed bronchoalveolar lavage

Key exclusion criteria

1) Patients with pre-existing PF-ILDs (e.g. idiopathic pulmonary fibrosis, collagen vascular disease-associated interstitial lung diseases, chronic hypersensitivity pneumonitis, etc.)
2) Patients with chronic respiratory failure
3) Patients with cardiac failure or fluid overload
4) Non-English studies
5) Studies of less than 10 patients with severe respiratory failure who were assessed for BAL

Target sample size

0


Research contact person

Name of lead principal investigator

1st name Keisuke
Middle name
Last name Anan

Organization

Graduate School of Medicine and Public Health, Kyoto University

Division name

Department of Healthcare Epidemiology

Zip code

606-8501

Address

Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan

TEL

075-753-4646

Email

ekusiek_7@yahoo.co.jp


Public contact

Name of contact person

1st name Keisuke
Middle name
Last name Anan

Organization

Graduate School of Medicine and Public Health, Kyoto University

Division name

Department of Healthcare Epidemiology

Zip code

606-8501

Address

Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan

TEL

075-753-4646

Homepage URL


Email

ekusiek_7@yahoo.co.jp


Sponsor or person

Institute

Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University

Address

Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan

Tel

075-753-4646

Email

ekusiek_7@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2020 Year 05 Month 31 Day

Date of IRB

2020 Year 06 Month 01 Day

Anticipated trial start date

2020 Year 06 Month 01 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

<Search method>
MEDLINE, etc.
<Assessment of risk of bias in included studies>
Two independent review authors will assess the risk of bias of the included studies using Newcastle-Otawa Scale tool or McMaster Quality Assessment Scale for Harms (McHarm). We will resolve discrepancies through discussion or consult a third review author if necessary.
<Meta-analysis>
We will use the Review Manager software (RevMan 5.1) and STATA ver.16.1 for statistical analysis. We will perform a quantitative analysis when studies are not heterogeneous. Random effects models will be used.
<Subgroup analysis>
We will perform the following subgroup analysis to investigate whether the frequencies of each adverse event are different among following the subgroups.
1. Age; younger than 65 years old, 65 years old or older
2. Mechanical ventilation when performing BAL; yes, no
3. The amount of BAL; 100~300ml (in accordance with the official American Thoracic Society clinical practice guideline), other (author definition)
<Sensitivity analysis>
We will perform the sensitivity analysis by excluding from the meta-analysis studies at high risk of bias of Newcastle-Otawa Scale tool.
<Summary of findings table>
We will create a summary of findings table for the following items;
participant, setting, description of BAL, number and percentage of deaths and serious sequelae, number and percentage of life-threatening adverse events (e.g., exacerbation of respiratory status requiring further treatment, arrhythmia requiring intervention, blood pressure reduction requiring intervention, etc.), number and percentage of minor adverse events (e.g., transient loss of oxygenation), quality assessment and comments


Management information

Registered date

2020 Year 05 Month 31 Day

Last modified on

2021 Year 10 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046332


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name